Shedding light on brain oxygenation
Summary
Our research group, led by Dr. Jeff Dunn, has identified low oxygen levels – a condition known as hypoxia, in the brain of 33% of people with Multiple Sclerosis (MS). We are currently conducting a research study to explore how hypoxia relates to symptoms, brain function, and progression.
We apply safe, non-invasive techniques, including near-infrared spectroscopy (NIRS) and electroencephalography (EEG), to measure brain oxygen levels and function. We also conduct MRI scans and collect a blood sample to identify physiological markers, such as inflammation, changes in brain structure and blood flow, and disease progression, as indicated by lesion load and brain atrophy.
All techniques used in our study are safe. Participants may choose to take part in one or more components of the study.
By comparing results from healthy participants and participants with MS, we aim to better understand how changes in brain oxygen and physiology may be linked to brain function and disease progression.
If you are interested in learning more, please fill out the short form below. Our research team will contact you to discuss the study and review eligibility criteria.
Eligibility
Eligible ages: 18 to 75
Accepts healthy participants: Yes
Inclusion criteria:
Age 18-75
Men and women
Clinical diagnosis of MS
Non-smoker (Nicotine or Marijuana)
Selection criteria - Healthy Participants:
Age 18-75
Men and women
Non-smoker (Nicotine or Marijuana)
No recent systemic infection
Otherwise healthy
No history of cardiovascular/vascular disease
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
If you are interested in participating in this study, or if you would like more information, please contact us at 403-2207849
Principal investigator:
Jeffrey Frank Dunn
Clinical trial:
No
REB-ID:
REB19-1105